BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Average Rating of “Moderate Buy” by Brokerages

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) have received a consensus rating of “Moderate Buy” from the sixteen analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eleven have assigned a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $140.1029.

Several brokerages recently commented on BNTX. Leerink Partners cut shares of BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 price objective for the company. in a research note on Monday, February 2nd. UBS Group upgraded BioNTech to a “hold” rating in a report on Thursday, December 4th. The Goldman Sachs Group raised BioNTech from a “neutral” rating to a “buy” rating and raised their price objective for the company from $115.00 to $142.00 in a research note on Friday, January 16th. Berenberg Bank restated a “buy” rating on shares of BioNTech in a research report on Friday, January 23rd. Finally, Morgan Stanley restated an “overweight” rating and set a $134.00 price objective on shares of BioNTech in a research report on Monday, November 3rd.

BioNTech Price Performance

BioNTech stock opened at $110.89 on Friday. The company has a market cap of $24.97 billion, a P/E ratio of -42.16 and a beta of 1.49. BioNTech has a one year low of $81.20 and a one year high of $124.00. The business has a fifty day moving average of $104.88 and a two-hundred day moving average of $103.43. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.02 and a current ratio of 7.12.

Institutional Trading of BioNTech

A number of large investors have recently made changes to their positions in BNTX. Dodge & Cox increased its position in BioNTech by 315.7% during the 3rd quarter. Dodge & Cox now owns 3,647,091 shares of the company’s stock worth $359,676,000 after purchasing an additional 2,769,654 shares in the last quarter. GSK plc acquired a new stake in shares of BioNTech during the 4th quarter worth about $84,711,000. BNP Paribas Financial Markets grew its holdings in shares of BioNTech by 43.0% during the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock worth $150,235,000 after buying an additional 474,796 shares in the last quarter. Bank of America Corp DE raised its position in shares of BioNTech by 344.4% in the third quarter. Bank of America Corp DE now owns 573,356 shares of the company’s stock valued at $56,544,000 after buying an additional 444,332 shares during the last quarter. Finally, Voloridge Investment Management LLC purchased a new position in shares of BioNTech during the fourth quarter valued at approximately $41,656,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.